BioLineRx Ltd. Files March 2024 Report on Form 6-K
Ticker: BLRX · Form: 6-K · Filed: Apr 10, 2024 · CIK: 1498403
| Field | Detail |
|---|---|
| Company | Biolinerx LTD. (BLRX) |
| Form Type | 6-K |
| Filed Date | Apr 10, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer
TL;DR
BioLineRx filed a 6-K for March 2024, mostly boilerplate but check Exhibit 1 for news.
AI Summary
BioLineRx Ltd. announced on April 10, 2024, the issuance of a press release filed as Exhibit 1 to this Form 6-K. The press release is for the month of March 2024 and is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Why It Matters
This filing provides an update on BioLineRx Ltd.'s activities and disclosures for the month of March 2024, which is important for investors to stay informed about the company's regulatory compliance and operational status.
Risk Assessment
Risk Level: low — This filing is a routine report of a foreign private issuer and does not contain significant new financial or operational information beyond what is typically disclosed in such reports.
Key Players & Entities
- BioLineRx Ltd. (company) — Registrant
- April 10, 2024 (date) — Announcement Date
- March 2024 (date) — Reporting Period
- 001-35223 (company) — Commission file number
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, for the month of March 2024.
When was the press release mentioned in the filing issued?
The press release was issued on April 10, 2024.
What is the company's principal executive office address?
The company's principal executive offices are located at 2 HaMa’ayan Street, Modi’in 7177871, Israel.
Does BioLineRx Ltd. file annual reports under Form 20-F or Form 40-F?
BioLineRx Ltd. files annual reports under Form 20-F.
What is the Commission file number for BioLineRx Ltd.?
The Commission file number for BioLineRx Ltd. is 001-35223.
Filing Stats: 182 words · 1 min read · ~1 pages · Grade level 10.9 · Accepted 2024-04-10 07:24:44
Filing Documents
- zk2431273.htm (6-K) — 9KB
- exhibit_1.htm (EX-99) — 17KB
- image00001.jpg (GRAPHIC) — 403KB
- 0001178913-24-001285.txt ( ) — 582KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant's name into English) 2 HaMa'ayan Street Modi'in 7177871, Israel (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F On April 10, 2024, the registrant issued the press release which is filed as Exhibit 1 to this Report on Form 6-K. The first paragraph of the press release attached to this Form 6-K is hereby incorporated by reference into all effective registration Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioLineRx Ltd. By: /s/ Philip A. Serlin Philip A. Serlin Chief Executive Officer Dated: April 10, 2024